ArcticZymes Technologies — Investor Presentation 2014

Apr 10, 2014

Svein W. F. Lien – CEO At the:

Biotec Pharmacon

Public in Oslo Stock Exchange Ticker: biotec

Beta-Glucan

• Proprietary beta-glucans showing documented effect in wound care
• The first product Woulgan® Biogel, has just been CE marked for use in advanced topical ulcers/wounds
• Large market in need of new product
• Pharma path retained through partner interest and dormant development programs

Enzymes – ArcticZymes

Tromsø

• Business based on unique cold adapted enzymes
• Core role in PCR contamination control
• Strong IP position for marketed products
• Large unexploited market
• Strong pipeline secured through strategic alliances and acquisition

20 years of research in key areas – strong IP based science

Agenda

Business areas

Beta-Glucans – advanced wound care

• Enzymes molecular testing
• Summary

Woulgan® Biogel – advanced wound healing

• Unique product based on proprietary beta-glucans
• Advanced medical device; Class 3, Rule 13 – can argue for an ancillary medicinal product effect
• CE mark received last week
• Agreement with Smith & Nephew

collaboration

• Market evaluation trials commencing upon CE-mark
• Evaluation in limited number of centres across Europe
• Seeking to establish end-user efficacy in routine clinical setting
• Obtaining planning tools and parameters for commercial strategy
• Clarifying the basis for a long-term relationship with Smith & Nephew, who hold exclusive, non-transferable technology rights until end of trials
• Biotec BetaGlucans are also actively contacting opinion leaders and the professional wound healing market in general
• Promoting the product and obtaining information about the competitiveness and market potential
• Web-shop about to be launched

6

The SBG substance is well documented

The animal study in diabetic mice shows that the performance of the reformulated SBG product (Woulgan®) with proven stability and well above typical moister gels used for wound healing

Placebo controlled double blinded study of 60 patients Statistical significant after 8 weeks

Documented effect on diabetic ulcers, scope to be expanded to other advanced wound healing applications

Advanced classification enables claiming of medical effects in labels and marketing

• Supported by article publication in 2014 Journal of Diabetes

"Macrophage stimulating agent soluble yeast b-1,3/1,6-glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo-controlled phase II study"

• Shows clear beneficial effect of SBG treatment in healing of diabetic foot ulcers
• Ancillary claims offer a unique opportunity for a gel in the wound market
• Significantly more efficacious wound healing than gels without SBG or occlusive secondary dressings alone
• Modulates the immunological system by activating macrophages and other phagocytic cells having specific cell receptors for SBG, and supports the natural wound healing process within the wound bed
• Exercises biological effects in terms of increased wound contraction, while allowing increased influx of phagocytic cells to the wound bed
• Attracting and stimulating phagocytic cells in the wound has potential for reducing risk of contamination and microbial infection in the wound bed ⁷

First launch in Europe The European Market Opportunity

Market estimate of annual number of wounds

Population	571 mill
# of Diabetic Foot Ulcer	2.0 million
# of Leg Ulcers	0.9 million
# of Pressure Ulcers	5.0 million
# of burns	1.0 million
Europe is about 30% - 50% of world market, dependent on definitions

Woulgan ⁸ ® - an advanced wound healing product for general use

Agenda

Business areas and Highlights

Beta-Glucans – advanced wound care

Enzymes – molecular testing

Summary

• Several well known cold adapted enzymes for use in molecular biology
• Unique heat inactivity features
• Used in PCR sample preparation
• Widely used by many research kit manufacturers
• Entering routine diagnostics through OEM agreements
• Customer base quickly expanding

Broadening the product base

• Shrimp Alkaline Phosphatase (SAP): has become one of today's most-selling DNA modifying enzymes due to the added convenience through a complete heat inactivation
• Cod Uracil-DNA Glycosylase (Cod UNG): from Atlantic Cod is the only commercially available UNG enzyme that is completely and irreversibly inactivated by moderate heat treatment.
• Nucleases originating from cold adapted marine organisms:
• dsDNase is double-strand DNA specific, especially useful in RNA or double-strand DNA clean-up applications
• HL-dsDNase is also heat-labile
• SAN is active at low temperatures and in high concentrations of salt, which makes it useful for applications where nucleic acids must be removed from samples
• HL-SAN is also heat-labile and will be launched later this year

Agreements with a number of the largest companies in the industry

Agenda

• Business areas and Highlights
• Beta-Glucans– advanced wound care
• Enzymes – molecular testing
• Summary and Outlook

Summary and Outlook

Beta Glucans:

• The launch of Woulgan® Biogel represent a game changer for this company
• Very favorable market response to this product

Enzymes:

• Establishing commercial relations with most of the larger players in the molecular diagnostics and research market. Appointing a limited number of regional distributors for sale of own label products

After fund raising this week company holds nearly GBP 10M cash – no debt

Questions?

Svein W. F. Lien Mob: +4792289323 Email: sl@biotec.no www.biotec.no